Pulmonx to Present at the Stifel 2024 Healthcare Conference
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Stifel 2024 Healthcare Conference. The company will engage in a fireside chat on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET in New York.
Interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of the Pulmonx website at https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG), leader nei trattamenti minimamente invasivi per gravi malattie polmonari, ha annunciato la propria partecipazione alla Stifel 2024 Healthcare Conference. L'azienda parteciperà a una chiacchierata informale martedì 19 novembre 2024, alle 6:10 AM PT / 9:10 AM ET a New York.
Le parti interessate possono accedere sia alle dirette che alle registrazioni delle presentazioni attraverso la sezione 'Investitori' del sito web di Pulmonx all'indirizzo https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG), líder en tratamientos mínimamente invasivos para enfermedades pulmonares severas, ha anunciado su participación en la Stifel 2024 Healthcare Conference. La empresa participará en una charla informal el martes 19 de noviembre de 2024, a las 6:10 AM PT / 9:10 AM ET en Nueva York.
Las partes interesadas pueden acceder tanto a las transmisiones en vivo como a las grabaciones de la presentación a través de la sección 'Inversores' del sitio web de Pulmonx en https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG)는 심각한 폐 질환에 대한 최소 침습적 치료의 선두주자로서 Stifel 2024 Healthcare Conference에 참석할 것이라고 발표했습니다. 회사는 2024년 11월 19일 화요일 오전 6:10 PT / 오전 9:10 ET에 뉴욕에서 화상 대화에 참여할 예정입니다.
관심 있는 당사자는 Pulmonx 웹사이트의 '투자자' 섹션을 통해 발표의 실시간 및 저장된 웹캐스트를 볼 수 있습니다. 링크: https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG), un leader dans les traitements minimement invasifs pour les maladies pulmonaires sévères, a annoncé sa participation à la Stifel 2024 Healthcare Conference. L'entreprise participera à une discussion informelle le mardi 19 novembre 2024, à 6h10 PT / 9h10 ET à New York.
Les parties intéressées peuvent accéder aux webinaires en direct et aux archives de la présentation via la section 'Investisseurs' du site web de Pulmonx à l'adresse https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG), ein führendes Unternehmen im Bereich minimalinvasiver Behandlungen von schweren Lungenerkrankungen, hat seine Teilnahme an der Stifel 2024 Healthcare Conference bekannt gegeben. Das Unternehmen wird am Dienstag, den 19. November 2024, um 6:10 Uhr PT / 9:10 Uhr ET in New York an einem Fireside-Chat teilnehmen.
Interessierte Parteien können sowohl Live- als auch archivierte Webcasts der Präsentation über den Bereich 'Investoren' auf der Website von Pulmonx unter https://investors.pulmonx.com/ abrufen.
- None.
- None.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When is Pulmonx (LUNG) presenting at the Stifel 2024 Healthcare Conference?
How can I watch Pulmonx's (LUNG) presentation at the Stifel Healthcare Conference?
What type of presentation will Pulmonx (LUNG) give at the Stifel 2024 Conference?
Where is the Stifel 2024 Healthcare Conference featuring Pulmonx (LUNG) being held?
